In Review: PCMA testified in the Human Services Committee on SB 11 and HB 7192. Both bills result from the Rx Drug Task Force, which met over the past few months. Both bills include delinking, fiduciary to the health plan sponsor, and a ban on spread pricing. Both bills passed out of committee. PCMA will continue to meet with legislators regarding our concerns about the bills. Previously, PCMA testified in opposition to SB 10, which would require PBMs to provide the burden of proof that a medication is not needed. The bill passed out of the Insurance and Real Estate Committee. The Connecticut Insurance Department released its 2025 Pharmacy Benefits Manager Rebate Report. In the calendar year 2024, PBMs, in the aggregate, retained 1.1% of all pharmaceutical manufacturer rebates they collected.

If you have any questions, please contact Sam Hallemeier at shallemeier@pcmanet.org.